Milestone for Ver-A-T1D
09. February 2022
On Monday February 8th, Medizinische Universität Graz celebrated the final visit of the very first participant in the Ver-A-T1D trial.
The blood pressure lowering drug Verapamil has shown to protect and strengthen beta cells and slowing down beta cell destruction in type 1 diabetes. INNODIA is very thankful for the participant who's happy to remain in follow-up for the next 12 months. Congrats to the team!